Menu
×
West Ashley Library
Closed
Phone: (843) 766-6635
Main Library
2 p.m. – 5 p.m.
Phone: (843) 805-6930
Wando Mount Pleasant Library
Closed
Phone: (843) 805-6888
McClellanville Library
Closed
Phone: (843) 887-3699
Folly Beach Library
Closed
Phone: (843) 588-2001
Miss Jane's Building (Edisto Library Temporary Location)
Closed for renovations
Phone: (843) 869-2355
John L. Dart Library
Closed
Phone: (843) 722-7550
St. Paul's/Hollywood Library
Closed
Phone: (843) 889-3300
Mt. Pleasant Library
Closed
Phone: (843) 849-6161
Dorchester Road Library
Closed
Phone: (843) 552-6466
Edgar Allan Poe/Sullivan's Island Library
Closed
Phone: (843) 883-3914
John's Island Library
Closed
Phone: (843) 559-1945
Otranto Road Library
Closed
Phone: (843) 572-4094
Hurd/St. Andrews Library
Closed
Phone: (843) 766-2546
Baxter-Patrick James Island
Closed
Phone: (843) 795-6679
Bees Ferry West Ashley Library
Closed
Phone: (843) 805-6892
Village Library
Closed
Phone: (843) 884-9741
Keith Summey North Charleston Library
Closed
Phone: (843) 744-2489
Mobile Library
Closed
Phone: (843) 805-6909
Today's Hours
West Ashley Library
Closed
Phone: (843) 766-6635
Main Library
2 p.m. – 5 p.m.
Phone: (843) 805-6930
Wando Mount Pleasant Library
Closed
Phone: (843) 805-6888
McClellanville Library
Closed
Phone: (843) 887-3699
Folly Beach Library
Closed
Phone: (843) 588-2001
Miss Jane's Building (Edisto Library Temporary Location)
Closed for renovations
Phone: (843) 869-2355
John L. Dart Library
Closed
Phone: (843) 722-7550
St. Paul's/Hollywood Library
Closed
Phone: (843) 889-3300
Mt. Pleasant Library
Closed
Phone: (843) 849-6161
Dorchester Road Library
Closed
Phone: (843) 552-6466
Edgar Allan Poe/Sullivan's Island Library
Closed
Phone: (843) 883-3914
John's Island Library
Closed
Phone: (843) 559-1945
Otranto Road Library
Closed
Phone: (843) 572-4094
Hurd/St. Andrews Library
Closed
Phone: (843) 766-2546
Baxter-Patrick James Island
Closed
Phone: (843) 795-6679
Bees Ferry West Ashley Library
Closed
Phone: (843) 805-6892
Village Library
Closed
Phone: (843) 884-9741
Keith Summey North Charleston Library
Closed
Phone: (843) 744-2489
Mobile Library
Closed
Phone: (843) 805-6909
Patron Login
menu
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Jo, Jae-Cheol; Kim, Jin-Seok; Lee, Je-Hwan; Lee, Jung-Hee; Im, Seong Nam; Lee, Sang-Min; Yoon, Sung-Soo; Kim, In-Ho; Bae, Seong Hwa; Lee, Yoo Jin; Choi, Yunsuk; Lee, Won-Sik
- Source:
Annals of Hematology; 2021, Vol. 100 Issue 1, p189-196, 8p- Subject Terms:
- Source:
- Additional Information
- Subject Terms:
- Abstract: Given the unsatisfactory survival in patients who received high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) for peripheral T-cell lymphomas (PTCLs), we conducted a prospective trial of busulfan (Bu), etoposide (E), cytarabine (A), and melphalan (M) (BuEAM), including IV Bu instead of carmustine (BCNU) as in standard BEAM, as a high-dose regimen in such patients. This study evaluated the efficacy and toxicity of BuEAM as a high-dose regimen for ASCT in patients with T-cell lymphomas. The high-dose chemotherapy at seven centers in Korea included Bu (3.2 mg/kg IV qd from day 6 to day 5), E (200 mg/m2 IV bid on day 4 and day 3), A (1 g/m2 IV qd on day 4 and day 3), and M (140 mg/m2 IV qd on day 2). Eighty-one patients were enrolled in this study. The main subtypes were peripheral T-cell lymphoma, not other specified (n = 32, 39.5%), NK/T-cell lymphoma (n = 22, 27.5%), and angioimmunoblastic T-cell lymphoma (n = 12, 14.8%). Upfront and salvage ASCTs were performed in 65 (80.2%) and 16 (19.8%) patients, respectively. The disease status of the patients before ASCT was 54 patients (66.7%) with complete response and 27 patients (33.3%) with partial response. The common grade-III toxicities were anorexia (8.6%), diarrhea (7.4%), and stomatitis (4.9%). No veno-occlusive disorder was noted. Fifty-six (69.1%) and seven (8.6%) patients achieved complete and partial response, respectively, after ASCT, although 17 patients (21.0%) showed progressive disease. At a median follow-up duration of 49.3 months, the estimated 3-year progression-free survival and overall survival were 55.2% and 68.2% in all patients. The BuEAM high-dose regimen for ASCT was well tolerated and seemed to be effective in patients with T-cell lymphomas. [ABSTRACT FROM AUTHOR]
- Abstract: Copyright of Annals of Hematology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Contact CCPL
Copyright 2022 Charleston County Public Library Powered By EBSCO Stacks 3.3.0 [350.3] | Staff Login
No Comments.